Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …

Type 2 diabetes mellitus (T2DM) associated non-alcoholic fatty liver disease (NAFLD) is the
fourth-leading cause of death. Hyperglycemia induces various complications, including …

Non-alcoholic fatty liver disease (NAFLD) is a major health issue worldwide, frequently
associated with obesity and type 2 diabetes. Steatosis is the initial stage of the disease …

Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver
disease worldwide. Due to its association with obesity and diabetes and the fall in hepatitis …

Highlights•NAFLD is highly prevalent and affects at least one-third of the global
population.•Currently, there is no drug to cure NAFLD.•Fenofibrate is a PPARα agonist with …

Nonalcoholic fatty liver disease (NAFLD, including nonalcoholic fatty liver (NAFL) and
nonalcoholic steatohepatitis (NASH)) is a high-prevalence disorder, affecting about 1 billion …

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver
disease in Western countries, accounting for 20–30% of general population and reaching a …

Purpose Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver
disease, affecting 30% of the global population. NAFLD prevalence is particularly high in …

The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH)
and the high prevalence among individuals with type 2 diabetes has attracted the attention …

Background: Myocarditis is now one of the most fatal and morbid complications of COVID-
19. Many scientists have recently concentrated on this problem. Objectives: This study …